一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

Welcome to chemicalbook!
+1 (818) 612-2111
RFQ
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Biochemical Engineering>Biochemical Reagents>Agonist Inhibitors>Pretomanid
Pretomanid
  • Pretomanid
  • Pretomanid
  • Pretomanid
  • Pretomanid
  • Pretomanid

Pretomanid NEW

Price Get Latest Price
Package 10mg 50mg 100mg
Min. Order: 10mg
Supply Ability: 1000
Update Time: 2025-12-16

Product Details

Product Name: Pretomanid CAS No.: 187235-37-6
Min. Order: 10mg Purity: 99%+ HPLC
Supply Ability: 1000 Release date: 2025/12/16

Pretomanid

Article illustration

WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com

    • Product Number: P109000
      English Name: Pretomanid
      English Alias: (S)-2-nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
      CAS Number: 187235-37-6
      Molecular Formula: C??H??F?N?O?
      Molecular Weight: 359.26

    • Product Advantages

    • High purity and controllable crystal form:HPLC purity ≥99.5%, with crystal form consistency confirmed by XRD (X-ray diffraction), meeting the strict quality requirements of WHO and FDA for new drug APIs.

    • Outstanding stability:Purity decrease <1% after storage at 25°C/RH60% for 6 months, and degradation products <0.3% in high-temperature (60°C) accelerated tests, suitable for complex formulation processes and long-term storage.

    • Single chiral configuration:Defined (S)-configuration with optical purity ≥99.0% (determined by chiral HPLC), avoiding potential toxicity risks from the (R)-isomer and complying with ICH Q6A requirements for chiral drugs.


    • Applications

    • Research and development of new anti-tubercular drugs:As a novel nitroimidazole antibiotic, it is used for treating multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), exerting bactericidal effects by inhibiting Mycobacterium tuberculosis DNA synthesis.

    • Combination therapy regimens:Combined with bedaquiline and linezolid to form short-course chemotherapy regimens (e.g., the Nix-TB regimen), clinical trials show a cure rate of over 90% in a 6-month course.

    • Pharmacokinetic research:It has an oral bioavailability of approximately 80% and low plasma protein binding rate (<20%), facilitating distribution to infection foci and providing data support for clinical dosing optimization.


    • Background Description
      Pretomanid is a new anti-tubercular drug developed by TubercuLogix (USA), which received FDA accelerated approval in 2019 for combination therapy of adult MDR-TB. It has a unique mechanism of action, damaging mycobacterial DNA after activation by nitroreductase, with bactericidal activity against dormant bacteria. WHO global data shows approximately 500,000 new MDR-TB cases annually, with traditional therapies requiring long treatment courses (18-24 months) and low success rates (50-60%). The introduction of Pretomanid has significantly shortened treatment cycles and improved cure rates, making it a key drug listed in WHO’s core anti-tubercular drug inventory.

    • Research Status

    • Clinical research progress:Phase III clinical trials (NCT02371200) showed a sputum culture conversion rate of 89% in the Pretomanid combination treatment group at 6 months, significantly higher than the placebo group (28%). Long-term follow-up (5 years) showed a recurrence rate <5% with good safety (main adverse reactions: nausea, headache, incidence <15%).

    • Drug resistance mechanism research:Resistance to Pretomanid in M. tuberculosis is primarily associated with mutations in the ndh gene (encoding nitroreductase), with a mutation rate of 2-5%, and no widely resistant strains have been reported.

    • Synthesis process optimization:The latest process uses chiral phase-transfer catalysis technology with (S)-epichlorohydrin as the starting material, increasing the total yield to 45% (20% higher than early processes) while reducing waste discharge, in line with green chemistry principles.

    • Formulation development:Oral tablets (200mg/tablet) and lyophilized injections have been developed. The injection uses micronization technology to increase solubility (apparent solubility improved from 0.2mg/mL to 1.5mg/mL), suitable for patients with gastrointestinal absorption disorders.

NOTE!

We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!

WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com


NEW IN STOCK!

The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery! 





Company Profile Introduction

-

You may like

Recommended supplier

Product name Price   Suppliers Update time
VIP3Y
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
2026-06-12
VIP1Y
Hefei Lbao Physical & Chemical Science Co.,Ltd
2026-05-18
$41.00
VIP6Y
TargetMol Chemicals Inc.
2026-05-11
$1.00
VIP8Y
Career Henan Chemical Co
2019-07-12
VIP3Y
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
2026-06-12
INQUIRY
邻水| 巴南区| 明光市| 屯门区| 巴青县| 古交市| 甘谷县| 汕尾市| 桑植县| 青田县| 芷江| 西昌市| 米易县| 勃利县| 富蕴县| 澄江县| 道孚县| 寻乌县| 大理市| 监利县| 阿荣旗| 桂平市| 临洮县| 高安市| 壤塘县| 黑河市| 南靖县| 会东县| 彭水| 淮北市| 新兴县| 文化| 徐汇区| 池州市| 山阳县| 辉南县| 光山县| 赫章县| 东兰县| 资兴市| 濮阳县|